ISS Recommends Keros Therapeutics Shareholders Withhold Votes from Directors Ahead of Annual Meeting

Reuters

May 21, 2025

ISS Recommends Keros <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Shareholders Withhold Votes from Directors Ahead of Annual Meeting

ADAR1 Capital Management, the largest stockholder of Keros Therapeutics with 13.3% ownership, has announced that Institutional Shareholder Services (ISS), a leading proxy advisory firm, recommends stockholders withhold votes from directors Dr. Mary Ann Gray and Dr. Alpna Seth at Keros's upcoming Annual Meeting on June 4, 2025. ISS expressed concerns over the company's governance, highlighting the need for greater accountability. ADAR1 supports this recommendation, emphasizing the benefits of fresh, independent directors. Additionally, ADAR1 urges Keros to disclose the results of its strategic review before the meeting, as stockholders are required to vote without knowing the outcomes of the Board's strategic process.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via PR Newswire (Ref. ID: NY93005) on May 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2537980146"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537980146\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537980146?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-21 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537980146","market":"nz","top_or_hot":-1,"title":"ISS Recommends Keros Therapeutics Shareholders Withhold Votes from Directors Ahead of Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ISS Recommends Keros <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Shareholders Withhold Votes from Directors Ahead of Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ADAR1 Capital Management, the largest stockholder of Keros Therapeutics with 13.3% ownership, has announced that Institutional Shareholder Services (ISS), a leading proxy advisory firm, recommends stockholders withhold votes from directors Dr. Mary Ann Gray and Dr. Alpna Seth at Keros's upcoming Annual Meeting on June 4, 2025. ISS expressed concerns over the company's governance, highlighting the need for greater accountability. ADAR1 supports this recommendation, emphasizing the benefits of fresh, independent directors. Additionally, ADAR1 urges Keros to disclose the results of its strategic review before the meeting, as stockholders are required to vote without knowing the outcomes of the Board's strategic process.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via PR Newswire (Ref. ID: NY93005) on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ISS Recommends Keros Therapeutics Shareholders Withhold Votes from Directors Ahead of Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nISS Recommends Keros Therapeutics Shareholders Withhold Votes from Directors Ahead of Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-21 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ISS Recommends Keros <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Shareholders Withhold Votes from Directors Ahead of Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ADAR1 Capital Management, the largest stockholder of Keros Therapeutics with 13.3% ownership, has announced that Institutional Shareholder Services (ISS), a leading proxy advisory firm, recommends stockholders withhold votes from directors Dr. Mary Ann Gray and Dr. Alpna Seth at Keros's upcoming Annual Meeting on June 4, 2025. ISS expressed concerns over the company's governance, highlighting the need for greater accountability. ADAR1 supports this recommendation, emphasizing the benefits of fresh, independent directors. Additionally, ADAR1 urges Keros to disclose the results of its strategic review before the meeting, as stockholders are required to vote without knowing the outcomes of the Board's strategic process.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via PR Newswire (Ref. ID: NY93005) on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KROS","symbol_name":"Keros Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDLbzR99N:1","article_id":"2537980146","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537980146","pubTimestamp":1747828888,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ADAR1 Capital Management, the largest stockholder of Keros Therapeutics with 13.3% ownership, has announced that Institutional Shareholder Services , a leading proxy advisory firm, recommends stockholders withhold votes from directors Dr. Mary Ann Gray and Dr. Alpna Seth at Keros's upcoming Annual Meeting on June 4, 2025. ISS expressed concerns over the company's governance, highlighting the need for greater accountability. ADAR1 supports this recommendation, emphasizing the benefits of fresh, independent directors. Additionally, ADAR1 urges Keros to disclose the results of its strategic review before the meeting, as stockholders are required to vote without knowing the outcomes of the Board's strategic process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inves","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KROS":"Keros Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"ISS建议Keros Therapeutics股东在年会前拒绝董事投票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KROS":0.9},"content_text":"ISS Recommends Keros Therapeutics Shareholders Withhold Votes from Directors Ahead of Annual Meeting\n    \n\n        ADAR1 Capital Management, the largest stockholder of Keros Therapeutics with 13.3% ownership, has announced that Institutional Shareholder Services (ISS), a leading proxy advisory firm, recommends stockholders withhold votes from directors Dr. Mary Ann Gray and Dr. Alpna Seth at Keros's upcoming Annual Meeting on June 4, 2025. ISS expressed concerns over the company's governance, highlighting the need for greater accountability. ADAR1 supports this recommendation, emphasizing the benefits of fresh, independent directors. Additionally, ADAR1 urges Keros to disclose the results of its strategic review before the meeting, as stockholders are required to vote without knowing the outcomes of the Board's strategic process.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via PR Newswire (Ref. ID: NY93005) on May 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}